Search results for " Leukaemia"

showing 10 items of 58 documents

Air pollution and childhood leukaemia: a nationwide case-control study in Italy

2013

Objectives Leukaemia is the most common cancer in children, but its aetiology is still poorly understood. We tested the hypothesis that traffic-related air pollution is associated with paediatric leukaemia because of chronic exposure to several potential carcinogens. Methods The Italian SETIL study (Study on the aetiology of lymphohematopoietic malignancies in children) was conducted in 14 Italian regions. All incident cases of leukaemia in children aged ≤10 years from these regions (period 1998–2001) were eligible for enrolment. Two controls per case, matched on birth date, gender and region of residence were randomly selected from the local population registries. Exposure assessment at bi…

MalePediatricsAir pollutionNO2Land use Regression ModelLogistic regressionmedicine.disease_causeEconomicaResidence CharacteristicsUSE REGRESSION-MODELSMedicineChildChildrenVehicle EmissionsGeneral Environmental ScienceUSE REGRESSION-MODELS RESIDENTIAL TRAFFIC DENSITY MAGNETIC-FIELDS POOLED ANALYSIS RISK-FACTOR CANCER EXPOSURE CHILDREN NO2 ASSOCIATIONLeukemiaIncidenceIncidence (epidemiology)ASSOCIATIONCANCERChildhood leukaemiaItalyChild PreschoolFemaleCase-Control StudieHumanmedicine.medical_specialtySocio-culturaleMAGNETIC-FIELDSPOOLED ANALYSISRISK-FACTORAir PollutionOccupational ExposureEnvironmental healthTraffic IndicatorHumansEXPOSURERESIDENTIAL TRAFFIC DENSITYExposure assessmentVehicle Emissionbusiness.industryPublic Health Environmental and Occupational HealthCase-control studyAmbientaleInfantCarcinogens EnvironmentalAutomobileCase-Control StudiesResidence CharacteristicDispersion ModelEtiologyGeneral Earth and Planetary SciencesParticulate MatterResidencebusinessAutomobilesOccupational and Environmental Medicine
researchProduct

SETIL: Italian multicentric epidemiological case–control study on risk factors for childhood leukaemia, non hodgkin lymphoma and neuroblastoma: study…

2014

Background Aetiology of childhood leukaemia and childhood neoplasm is poorly understood. Information on the prevalence of risk factors in the childhood population is limited. SETIL is a population based case–control study on childhood leukaemia, conducted with two companion studies on non-Hodgkin Lymphoma (NHL) and neuroblastoma. The study relies on questionnaire interviews and 50 Hz magnetic field (ELF-MF) indoor measurements. This paper discusses the SETIL study design and includes descriptive information. Methods The study was carried out in 14 Italian regions (78.3% of Italian population aged 0–10). It included leukaemia, NHL and neuroblastoma cases incident in 0–10 year olds in 1998–20…

MalePediatricsPassive smokingLymphomaEpidemiologyNon hogdkin lymphomamedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataNeuroblastomaEconomicahemic and lymphatic diseasesEpidemiologyPrevalencerisk factorsLeukaemiaChildeducation.field_of_studyIncidence (epidemiology)IncidenceLymphoma Non-Hodgkinnon hodgkin lymphoma and neuroblastomaEnvironmental exposureItalyChild PreschoolPopulation studyFemaleHumanmedicine.medical_specialtyPopulationNon-HodgkinSocio-culturalestudy populationRisk Assessmentchildhood leukaemiamedicineHumanseducationPreschoolPregnancybusiness.industryResearchrisk factors; childhood leukaemia; non hodgkin lymphoma and neuroblastoma; study populationCase-control studyInfant NewbornAmbientaleInfantEnvironmental Exposuremedicine.diseaseNewbornbusiness
researchProduct

Incidence, time trends and regional variation of childhood leukaemia in Germany and Europe.

2008

This paper presents data on the German and Europe-wide incidence, time trends and regional variations of childhood leukaemia. Data were provided by the German Childhood Cancer Registry (GCCR), a population-based cancer registry recording all cases of malignant diseases in children under 15 y of age residing in Germany and by the Automated Childhood Cancer Information System (ACCIS) co-ordinated at International Agency for Research on Cancer, Lyon, that combines and evaluates data from several European population-based cancer registries. The incidence of leukaemia (44.0 per million) has increased in Europe as well as in Germany in the last decades (0.6% annually on average). Germany shows no…

MalePediatricsmedicine.medical_specialtyAdolescentPopulationDisease OutbreaksGermanGermanymedicineHumansRadiology Nuclear Medicine and imagingRegistrieseducationChildChildhood Cancer Registryeducation.field_of_studyRadiationLeukemiaRadiological and Ultrasound TechnologyIncidence (epidemiology)IncidencePublic Health Environmental and Occupational HealthInfant NewbornCancerInfantGeneral Medicinemedicine.diseaselanguage.human_languageChildhood leukaemiaCancer registryEuropeGeographyRegional variationChild PreschoollanguageFemaleDemographyRadiation protection dosimetry
researchProduct

Hepatitis B virus reactivation and alemtuzumab therapy

2005

Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immmunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab the…

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaHepatitis B virusHBsAgCD52Antibodies Neoplasmmedicine.medical_treatmenthepatitis B viruAntibodies Monoclonal Humanizedmedicine.disease_causeCampath-1HSettore MED/15 - Malattie Del SanguemedicineHumansAlemtuzumabImmunosuppression TherapyHepatitisHepatitis B virusSettore MED/12 - GastroenterologiaHepatitis B Surface Antigensbusiness.industryacute hepatitiAntibodies Monoclonalvirus diseasesLamivudineImmunosuppressionHematologyGeneral MedicineMiddle AgedHepatitis BHepatitis Bmedicine.diseaseLeukemia Lymphocytic Chronic B-Celldigestive system diseasesLamivudineDNA ViralImmunologyReverse Transcriptase InhibitorsAlemtuzumabFemaleVirus Activationbusinesschronic lymphocytic leukaemiamedicine.drugEuropean Journal of Haematology
researchProduct

Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA).

2014

SummaryAcute pulmonary embolism (PE) is a serious complication in association with malignant diseases. We describe the successful treatment of PE applying a systemic thrombolytic therapy in a 4-year-old boy with acute lymphoblastic leukaemia.The thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) 0.1 mg/ kg bodyweight per hour for six hours was continued for six days without important side effects. In particular no bleeding complications were observed. Computed tomography with contrast revealed a remarkable regression of the central PE. Without further delays the chemotherapy was resumed.

Malemedicine.medical_specialtyLeukemia T-Cellmedicine.medical_treatmentComputed tomographyFibrinolytic AgentsmedicineHumansRecombinant tissue plasminogen activatorChemotherapymedicine.diagnostic_testbusiness.industryAnticoagulantsHematologyHeparin Low-Molecular-Weightmedicine.diseaseRecombinant ProteinsSurgeryPulmonary embolismTreatment OutcomeChild PreschoolTissue Plasminogen ActivatorLymphoblastic leukaemiaDrug Therapy CombinationbusinessComplicationPulmonary EmbolismT cell leukaemiaHamostaseologie
researchProduct

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.

2009

OBJECTIVES: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. METHODS: Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified inten…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAspergillosisGastroenterologyTransplantation Autologouschemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultCaspofunginInternal medicineClinical endpointmedicineAspergillosisHumansPharmacology (medical)Survival rateSurvival analysisAgedPharmacologyAged 80 and overSurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationAcute Leukaemia; Fungal Infections; Echinocandins; Bone-Marrow-Transplantation; Stem-Cell Transplants; Mycoses Study-Group; Fungal-Infections; Prognostic-Factors; European-Organization; Amphotericin-B; Consensus; Epidemiology; VoriconazoleInfectious DiseasesTreatment OutcomechemistryHematologic NeoplasmsFemaleCaspofunginbusinessThe Journal of antimicrobial chemotherapy
researchProduct

The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia

2016

OncologyAcute promyelocytic leukemiaacute leukaemiamedicine.medical_specialtyacute promyelocytic leukaemiaPROTEÍNAS PROTO-ONCOGÊNICAS03 medical and health sciences0302 clinical medicineInternal medicinemedicineNeoplasmSurvival ratebusiness.industryFollow up studiesHematologymedicine.diseaseMinimal residual diseaseClinical trialLeukemiaPML/RARA; acute leukaemia; acute promyelocytic leukaemia; minimal residual disease; quantitative PCR030220 oncology & carcinogenesisquantitative PCRminimal residual diseaseAcute promyelocytic leukaemiabusinessPML/RARASettore MED/15 - Malattie del Sangue030215 immunology
researchProduct

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable resi…

2020

In the European LeukemiaNet favourable risk category, allogeneic haematopoietic stem cell transplantation (alloSCT) is not indicated in first complete remission for patients with acute myeloid leukaemia (AML) with NPM1 mutations (ELNfav NPM1 AML), although a proportion of these patients will relapse. Given the prognostic importance of measurable residual disease (MRD), CETLAM-12 considered a pre-emptive intervention in patients with molecular failure (MF). We analyzed 110 ELNfav NPM1 AML patients achieving complete remission (CR) after induction chemotherapy. Two-year cumulative incidence of relapse (CIR), overall survival (OS) and leukaemia-free survival (LFS) were 17%, 81 center dot 5% an…

OncologyAdultMalemedicine.medical_specialtyNPM1Neoplasm ResidualAdolescentDiseasestem cell transplantationDisease-Free Survival03 medical and health sciencesEuropean LeukemiaNet0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineHumansacute myeloid leukaemiamolecular analysisCumulative incidenceAgedbusiness.industryInduction chemotherapyMyeloid leukemiaNuclear ProteinsHematologyInduction ChemotherapyMiddle AgedNeoplasm ProteinsTransplantationEuropeSurvival RateHaematopoiesisLeukemia Myeloid Acute030220 oncology & carcinogenesisleukaemiaMutationFemalebusinessNucleophosmin030215 immunologyBritish journal of haematologyReferences
researchProduct

Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study

2015

BACKGROUND: Significant advances in the management of patients with lymphoid and myeloid malignancies entered clinical practice in the early 2000's. The EUROCARE-5 study database provides an opportunity to assess the impact of these changes at the population level by country in Europe. We provide survival estimates for clinically relevant haematological malignancies (HM), using the International Classification of Diseases for Oncology 3, by country, gender and age in Europe. METHODS: We estimated age-standardised relative survival using the complete cohort approach for 625, 000 adult patients diagnosed in 2000-2007 and followed up to 2008. Survival information was provided by 89 participati…

OncologyCancer registry; Europe; Hodgkin lymphoma; Leukaemia; Lymphoma; Multiple myeloma; Non-Hodgkin lymphoma; Relative survivalCancer Researcheducation.field_of_studymedicine.medical_specialtyMyeloidRelative survivalbusiness.industryPopulationFollicular lymphomaPlasma cell neoplasmmedicine.diseaseLymphomaCancer registrymedicine.anatomical_structureOncologyhemic and lymphatic diseasesInternal medicineImmunologyMedicineeducationbusinessInternational Classification of Diseases for OncologyEuropean Journal of Cancer
researchProduct

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective …

2017

Abstract Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Out…

OncologyMaleTransplantation ConditioningCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Chronic lymphocytic leukemiaMedizinQUALITY MANAGEMENT-SYSTEMKaplan-Meier Estimaterisk factor analysisGUIDELINESBiochemistryallogeneic stem cell transplantation; centre effects; chronic lymphocytic leukaemia; frailties; risk factor analysiscentre effectsTransplantation Conditioning / methods0302 clinical medicineRecurrenceRisk Factorsallogeneic stem cell transplantationLeukemia Lymphocytic Chronic B-Cell / mortalityRegistriesDelivery of Health Care / statistics & numerical dataIBRUTINIBddc:6160303 health sciencesALEMTUZUMABHazard ratioHematopoietic Stem Cell TransplantationProfessional PracticeHematologyMiddle Aged3. Good healthEurope030220 oncology & carcinogenesisABT-199CohortSURVIVALAlemtuzumabFemaleEurope / epidemiologymedicine.drugAdultmedicine.medical_specialtyAllogeneic transplantationImmunologyLower riskDIAGNOSISSettore MED/01 - Statistica Medica03 medical and health sciencesLeukemia Lymphocytic Chronic B-Cell / therapyHematopoietic Stem Cell Transplantation / methodsInternal medicinemedicineHumansKarnofsky Performance Status030304 developmental biologyAgedRetrospective Studiesbusiness.industryProportional hazards modelCHRONIC LYMPHOCYTIC-LEUKEMIARetrospective cohort studySTEM-CELL TRANSPLANTATIONCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryProfessional Practice / statistics & numerical dataTransplantationbusinessDelivery of Health Carefrailtieschronic lymphocytic leukaemia030215 immunologyRESPONSES
researchProduct